Budesonide / formoterol fumarate (SYMBICORT) vs mometasone furoate/formoterol fumarate
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Glucocorticoid receptor; Beta-2 adrenergic receptor · full Asthma pipeline
Budesonide / formoterol fumarate (SYMBICORT)
Marketed by AstraZeneca
NCT00646321 · Phase 3 · completed
The study was randomized and double-blind, used budesonide as an active comparator, and planned to enroll 540 participants. Its primary endpoint was change in evening peak expiratory flow, a lung-function surrogate rather than a hard clinical or endoscopic outcome, and no primary endpoint results are posted.
Reported efficacy
Change in evening PEF (Daily throughout the 12 week treatment period): Evening PEF (primary) better with once- or twice-daily budesonide/formoterol than budesonide alone (P<or=.027). (met)
Result source: NCT00646321
mometasone furoate/formoterol fumarate · Dulera / Zenhale
Marketed by Organon and partners
NCT00746330 · Phase 2 · completed
The study randomized and quadruple-blinded 32 children to receive the combination, active comparators, and placebo in a crossover design. Its primary endpoint was the surrogate measure of 12-hour FEV1 AUC; although the reported means favored the combination over placebo, statistical significance was not stated, so the result is unclear.
Reported efficacy
Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 12 in Forced Expiratory Volume (Liters) in 1 Second (FEV1) for MF/F Versus MF (Baseline to Endpoint (12 weeks)); Time-to-first Asthma Exacerbation Over the 26-week Treatment Period for the Comparison of MF/F Versus F: Primary endpoint (FEV1 AUC(0-12h) change from baseline to week 12, L*h), MF/F 200/10 mcg vs MF 200 mcg alone: 3.19 (SD 3.98) vs 1.31 (SD 3.98); p<.001. (mixed)
Result source: NCT00383240
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Budesonide / formoterol fumarate (SYMBICORT) | mometasone furoate/formoterol fumarate |
|---|---|---|
| Severe exacerbations, annualised rate | —Not posted · NCT00646321 | —Not reported |
| Trough FEV1, change | 0.2 vs 0.1vs BudesonideNCT00702325 | —Not reported |
| ACQ-5, change | —Not posted · NCT00646321 | —Not reported |
| OCS dose reduction | —Not posted · NCT00646321 | —Not reported |
Severe exacerbations, annualised rate
- Budesonide / formoterol fumarate (SYMBICORT)
- —Not posted · NCT00646321
- mometasone furoate/formoterol fumarate
- —Not reported
Trough FEV1, change
- Budesonide / formoterol fumarate (SYMBICORT)
- 0.2 vs 0.1vs BudesonideNCT00702325
- mometasone furoate/formoterol fumarate
- —Not reported
ACQ-5, change
- Budesonide / formoterol fumarate (SYMBICORT)
- —Not posted · NCT00646321
- mometasone furoate/formoterol fumarate
- —Not reported
OCS dose reduction
- Budesonide / formoterol fumarate (SYMBICORT)
- —Not posted · NCT00646321
- mometasone furoate/formoterol fumarate
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Budesonide / formoterol fumarate (SYMBICORT): 4 of 4 rows · mometasone furoate/formoterol fumarate: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Budesonide / formoterol fumarate (SYMBICORT) | mometasone furoate/formoterol fumarate |
|---|---|---|
| Dropout rate | 24.4%a NCT00702325 · Phase 4 · registry result, not featured evidence show 2 more results0%With Spacer NCT00536913 · Phase 3 · registry result, not featured evidence 0%Without Spacer NCT00536913 · Phase 3 · registry result, not featured evidence | —b NCT00746330 · Phase 2 · combination · Asthma · phase 2 show 6 more results18.3%200/10 mcg BID NCT00383240 · Phase 3 19.8%100/10 mcg BID NCT00383552 · Phase 3 12.5%200/10 mcg MDI BID NCT01566149 · Phase 3 8%400/10 mcg MDI BID NCT01566149 · Phase 3 —MF/F MDI With Spacer NCT01258803 · Phase 2 · registry result, not featured evidence —MF/F MDI Without Spacer NCT01258803 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 0.6%a NCT00702325 · Phase 4 · registry result, not featured evidence show 2 more results—With Spacer NCT00536913 · Phase 3 · registry result, not featured evidence —Without Spacer NCT00536913 · Phase 3 · registry result, not featured evidence | —b NCT00746330 · Phase 2 · combination · Asthma · phase 2 show 6 more results2.1%200/10 mcg BID NCT00383240 · Phase 3 3.8%100/10 mcg BID NCT00383552 · Phase 3 0%200/10 mcg MDI BID NCT01566149 · Phase 3 4%400/10 mcg MDI BID NCT01566149 · Phase 3 —MF/F MDI With Spacer NCT01258803 · Phase 2 · registry result, not featured evidence —MF/F MDI Without Spacer NCT01258803 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 0.6%a NCT00702325 · Phase 4 · registry result, not featured evidence show 2 more results0%With Spacer NCT00536913 · Phase 3 · registry result, not featured evidence 0%Without Spacer NCT00536913 · Phase 3 · registry result, not featured evidence | 0%b NCT00746330 · Phase 2 · combination · Asthma · phase 2 show 6 more results2.6%200/10 mcg BID NCT00383240 · Phase 3 2.2%100/10 mcg BID NCT00383552 · Phase 3 0%200/10 mcg MDI BID NCT01566149 · Phase 3 0%400/10 mcg MDI BID NCT01566149 · Phase 3 0%MF/F MDI With Spacer NCT01258803 · Phase 2 · registry result, not featured evidence 0%MF/F MDI Without Spacer NCT01258803 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 200/10 mcg BIDb nasopharyngitis 6.3% (placebo 3.6%) upper respiratory tract infection 5.8% (placebo 8.7%) headache 4.7% (placebo 3.6%) NCT00383240 · Phase 3 show 3 more results100/10 mcg BID nasopharyngitis 9.3% (placebo 2.7%) headache 6.6% (placebo 3.7%) upper respiratory tract infection 5.5% (placebo 6.4%) NCT00383552 · Phase 3 200/10 mcg MDI BID upper respiratory tract infection 12.5% accidental overdose 4.2% asthma 4.2% NCT01566149 · Phase 3 |
Notes
- aPopulation comparability has not been reviewed for these studies.
- bPopulation comparability has not been reviewed for 6 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Budesonide / formoterol fumarate (SYMBICORT)
+ 14 further endpoints in the CSV export.
mometasone furoate/formoterol fumarate
show 4 more results
show 1 more result
show 1 more result
show 1 more result
+ 1 further endpoint in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Budesonide / formoterol fumarate (SYMBICORT)'s landscape · mometasone furoate/formoterol fumarate's landscape